Profile data is unavailable for this security.
About the company
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
- Revenue in CNY (TTM)35.67bn
- Net income in CNY-153.00m
- Incorporated2025
- Employees11.08k
- LocationBeOne Medicines AGc/o BeOne Medicines I GmbHAeschengraben 27BASEL 4051SwitzerlandCHE
- Phone+41 616851900
- Websitehttps://beonemedicines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaEssentia Corp | 3.04bn | 1.06bn | 60.51bn | 131.00 | 55.97 | 8.12 | 53.00 | 19.92 | 12.95 | 12.95 | 37.25 | 89.26 | 0.4345 | 1.23 | 4.84 | -- | 15.11 | -5.26 | 16.67 | -5.99 | 89.17 | 82.30 | 34.78 | -19.83 | 6.54 | 64.89 | 0.0291 | -- | 90.67 | 99.81 | 575.37 | -- | 40.94 | -- |
| Akeso Inc | 2.51bn | -846.95m | 85.74bn | 3.53k | -- | 12.97 | -- | 34.11 | -1.09 | -1.09 | 3.25 | 8.12 | 0.2115 | 0.7726 | 3.95 | 936,947.80 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.50bn | -722.97m | 86.28bn | 1.87k | -- | 17.19 | -- | 57.43 | -3.65 | -3.65 | 7.54 | 24.35 | 0.3067 | 4.93 | 13.37 | 925,245.40 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 20.08bn | 4.20bn | 146.29bn | 12.55k | 35.72 | 3.20 | 21.97 | 7.29 | 1.12 | 1.12 | 5.42 | 12.51 | 0.3442 | 6.36 | 3.06 | 1,806,232.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
| BeOne Medicines AG | 35.67bn | -153.00m | 294.74bn | 11.08k | -- | 13.71 | -- | 8.26 | -0.1999 | -0.1999 | 24.49 | 20.40 | 0.7516 | 1.47 | 7.05 | 3,221,068.00 | -0.3223 | -22.78 | -0.4778 | -30.07 | 85.99 | 83.69 | -0.4289 | -72.74 | 2.17 | 4.50 | 0.2209 | -- | 56.19 | 55.91 | 25.87 | -- | 40.78 | -- |
| WuXi AppTec Co Ltd | 44.40bn | 14.99bn | 308.03bn | 39.41k | 19.48 | 4.11 | -- | 6.94 | 5.23 | 5.23 | 15.49 | 24.80 | 0.5259 | 3.70 | 4.82 | 1,126,406.00 | 17.97 | 12.32 | 22.39 | 15.68 | 45.00 | 39.12 | 34.17 | 22.92 | 2.36 | -- | 0.0983 | 30.00 | -2.73 | 24.97 | -1.63 | 38.50 | 9.60 | 37.38 |
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 7.61m | 6.61% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 4.35m | 3.78% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 4.12m | 3.59% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 4.06m | 3.53% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 3.69m | 3.21% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 2.98m | 2.59% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.60m | 2.26% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.99m | 1.73% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 1.80m | 1.56% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.67m | 1.45% |
